Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naoluoshu ning granules
- Development stage
- Phase 2
- Lead developer
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
- Administration
- Oral
01
Overview
Naoluoshu Ning granules is a Traditional Chinese Medicine (TCM) formulation developed by the Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences. It is currently being evaluated in Phase II clinical trials for the treatment of mild-to-moderate vascular dementia. The formulation is specifically designed to treat patients exhibiting the TCM pattern of yin deficiency with yang hyperactivity and blood stasis (阴虚阳亢、瘀血阻络证). As a botanical-based therapy, it aims to improve cognitive function and manage symptoms associated with cerebrovascular-related cognitive impairment through a multi-target approach characteristic of herbal medicine.
- Other names
- Naoluoshu Ning granules脑络疏宁颗粒
Beyond the preview
Go deeper on naoluoshu ning granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naoluoshu ning granules.